Overweight and obesity are growing epidemiologic problems worldwide. Body mass index (BMI) defined as a person's weight in kilograms divided by the square of his height in meters (kg/m 2 ) is a simple measure in common use. 1 According to the WHO definition, people with a BMI X25 kg/m 2 are overweight and those with a BMI X30 kg/m 2 are obese. A raised BMI is recognized as a major risk factor for cardiovascular diseases, diabetes and musculoskeletal disorders, and also for a number of cancers, including non-Hodgkin's lymphoma and multiple myeloma. 2 Recently, it has been observed that BMI may correlate with the efficacy of stem-cell mobilization with standard regimens based on administration of granulocytecolony stimulating factor (G-CSF), and it has been suggested that this may be a result of the altered pharmacokinetics of G-CSF in obese individuals. [3] [4] [5] Moreover, hypercholesterolemia, which frequently accompanies increased BMI, seems to promote stem-cell mobilization, and this was documented in both an experimental murine model, and a retrospective analysis of clinical data. 6, 7 High cholesterol levels may interfere with the SDF-1/CXCR4 axis by induction of a proinflammatory state, activation of complement the cascade and an increase in serum SDF-1. Plerixafor is a new agent used in combination with G-CSF in myeloma and lymphoma patients, who failed a previous mobilization attempt. 8 The action of plerixafor is based on reversible disruption of the CXCR4/SDF-1 axis by specific inhibition of the CXCR4 receptor. We hypothesized that stem-cell mobilization with plerixafor might be impaired in overweight and obese individuals, who need to mobilize and collect more CD34 þ cells in total on the basis of their higher body weight. We investigated this in a group of 606 patients from 13 countries who were enrolled in the European plerixafor compassionate use program. The regimen of plerixafor and G-CSF administration was published elsewhere, 9, 10 and all patients signed the informed consent form for inclusion in the compassionate use program and for collection of their data. This retrospective analysis included a total of 356 patients for whom adequate data regarding BMI were available. Patient characteristics and mobilization features are summarized in Table 1 . There were no significant differences between the groups in regard to median age, disease profile, number of prior chemotherapy regimens, prior treatments, number of prior mobilization regimens, pre-mobilization WBC and platelet counts, and the regimen of mobilization with plerixafor. Statistical analysis revealed that the outcomes of stem-cell mobilization in patients with BMI X25 kg/m 2 did not differ significantly from that observed in the remaining patients ( Table 2 ). The median number of circulating CD34 þ cells was 23 in patients with BMI o25 kg/m 2 , and 20.6 in patients with BMI X25 kg/m 2 . Both groups required a median of 2 plerixafor injections. The median number of CD34 þ cells collected during the apheresis following the first plerixafor injection was 1.7 Â 10 6 cells/kg in both cohorts; however, there was a trend towards a higher proportion of patients with BMI o25 kg/m 2 yielding X2 Â 10 6 CD34 þ cells/kg during the first apheresis (47.2% vs 37.2% in patients with BMI X25 kg/m 2 , P ¼ 0.079). Finally, both groups of patients had a median of 3.12 Â 10 6
CD34
þ cells/kg and there were no significant differences in the proportions of patients who had at least 2, 4 or 5 Â 10 6
þ cells/kg in each group. The total dose of plerixafor was significantly higher in patients with BMI X25 kg/m 2 (median 40.1 mg) than in patients with BMI o25 kg/m 2 (median 27.8 mg, Po0.001). Our analysis revealed that an increased BMI does not impair the ability to collect the required CD34 þ cell dose after stem-cell mobilization with plerixafor and G-CSF. However, patients with BMI X25 kg/m 2 more frequently require more than one apheresis session to collect the minimum cell numbers. This, taken together with higher doses of plerixafor in overweight and obese patients, may contribute to the increased cost of the mobilization procedure. However, as it is not known how the excess of fatty tissue affects the distribution of the drug, as well as homing and engraftment of mobilized progenitor cells, this problem could be potentially overcome by calculating the dose of plerixafor and/or required dose of hematopoietic stem cells per kg of ideal body weight and not per kg of actual body weight in overweight and obese individuals. Further studies should therefore investigate whether these strategies could be applied in patients with BMI X25 kg/m 2 who are mobilized with plerixafor.
Conflict of interest
The authors have acted as consultants to Genzyme Corp. 
GW

